Introduction Measuring dietary adherence is essential while prescribing a diet plan for type 2 diabetes. This study aims to develop and validate a diabetes diet adherence scale (D-DAS) among type 2 diabetes patients in India.
{"title":"Reliability and Structure of Diabetes Diet Adherence Scale (D-DAS): A Follow-up Study among Type 2 Diabetes Patients of India","authors":"Savitesh Kushwaha, Rachana Srivastava, Sanjay Kumar Bhadada, Vivek Sagar, Poonam Khanna","doi":"10.1101/2024.05.25.24307586","DOIUrl":"https://doi.org/10.1101/2024.05.25.24307586","url":null,"abstract":"<strong>Introduction</strong> Measuring dietary adherence is essential while prescribing a diet plan for type 2 diabetes. This study aims to develop and validate a diabetes diet adherence scale (D-DAS) among type 2 diabetes patients in India.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141167053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-27DOI: 10.1101/2024.05.25.24307923
Heloisa Harumi Yamamoto, Thiago Fraga Napoli, João Eduardo Nunes Salles
Introduction Obesity is a chronic, prevalent, multifactorial disease, stigmatized and linked to multiple long-term complications, which makes the treatment currently available below of the expectations from what is necessary to combat it. Because of this limitation, off-label medications for the treatment of obesity, such as topiramate, have been widely used, in association with on-label medications, such as sibutramine, in order to achieve more effective weight loss.
{"title":"EFFICACY OF SIBUTRAMINE AND TOPIRAMATE COMBINATION IN WEIGHT LOSS: RETROSPECTIVE COHORT STUDY ON BRAZILIAN ADULTS","authors":"Heloisa Harumi Yamamoto, Thiago Fraga Napoli, João Eduardo Nunes Salles","doi":"10.1101/2024.05.25.24307923","DOIUrl":"https://doi.org/10.1101/2024.05.25.24307923","url":null,"abstract":"<strong>Introduction</strong> Obesity is a chronic, prevalent, multifactorial disease, stigmatized and linked to multiple long-term complications, which makes the treatment currently available below of the expectations from what is necessary to combat it. Because of this limitation, off-label medications for the treatment of obesity, such as topiramate, have been widely used, in association with on-label medications, such as sibutramine, in order to achieve more effective weight loss.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141167149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-10DOI: 10.1101/2024.05.10.24307180
Atinuke Wilton-Waddell, Layal Abi Farraj, Elton JR Vasconcelos, Emily Byrne, Angela E Taylor, Adrian Freeman, Damla Etal, Paul M Stewart, Wiebke Arlt, Ramzi Ajjan, Ana Tiganescu
Cortisol excess drives multiple adverse effects including hypertension, dyslipidemia, and delayed wound healing. Activation of cortisol by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has shown promise as a therapeutic target for these comorbidities but clinical progress has been hampered by variable 11β-HSD1 inhibitor efficacy. Here, transcriptomic profiling of 11β-HSD1 target genes in primary skin fibroblasts as well as skin biopsies from type 2 diabetes individuals treated with the selective 11β-HSD1 inhibitor AZD4017 provide detailed mechanistic insights highlighting new areas of therapeutic potential. We report correlations between changes in 11β-HSD1 target gene expression, blood pressure, lipids, and wound healing with 1) cortisol levels (serum cortisol / dehydroepiandrosterone sulfate) and 2) peripheral 11β-HSD1 activity (serum cortisol / cortisone). Finally, we demonstrate that baseline cortisol levels and changes in placebo group cortisol levels are key determinants of 11β-HSD1 inhibitor efficacy. In conclusion, our findings pave the way for more effective targeting of 11β-HSD1 inhibitor treatment, improving the accuracy of future clinical studies. Larger trials of longer duration are now warranted to fully explore the therapeutic potential of 11β-HSD1 inhibitors across a range of cardiometabolic and age-associated indications.
{"title":"11β-HSD1 inhibitor efficacy in type 2 diabetes is cortisol-dependent","authors":"Atinuke Wilton-Waddell, Layal Abi Farraj, Elton JR Vasconcelos, Emily Byrne, Angela E Taylor, Adrian Freeman, Damla Etal, Paul M Stewart, Wiebke Arlt, Ramzi Ajjan, Ana Tiganescu","doi":"10.1101/2024.05.10.24307180","DOIUrl":"https://doi.org/10.1101/2024.05.10.24307180","url":null,"abstract":"Cortisol excess drives multiple adverse effects including hypertension, dyslipidemia, and delayed wound healing. Activation of cortisol by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has shown promise as a therapeutic target for these comorbidities but clinical progress has been hampered by variable 11β-HSD1 inhibitor efficacy. Here, transcriptomic profiling of 11β-HSD1 target genes in primary skin fibroblasts as well as skin biopsies from type 2 diabetes individuals treated with the selective 11β-HSD1 inhibitor AZD4017 provide detailed mechanistic insights highlighting new areas of therapeutic potential. We report correlations between changes in 11β-HSD1 target gene expression, blood pressure, lipids, and wound healing with 1) cortisol levels (serum cortisol / dehydroepiandrosterone sulfate) and 2) peripheral 11β-HSD1 activity (serum cortisol / cortisone). Finally, we demonstrate that baseline cortisol levels and changes in placebo group cortisol levels are key determinants of 11β-HSD1 inhibitor efficacy. In conclusion, our findings pave the way for more effective targeting of 11β-HSD1 inhibitor treatment, improving the accuracy of future clinical studies. Larger trials of longer duration are now warranted to fully explore the therapeutic potential of 11β-HSD1 inhibitors across a range of cardiometabolic and age-associated indications.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-09DOI: 10.1101/2024.05.08.24306164
Noemi Gozzi, Lauren Chee, Ingrid Odermatt, Sanne Kikkert, Greta Preatoni, Giacomo Valle, Nikolai Pfender, Felix Beuschlein, Nicole Wenderoth, Carl Zipser, Stanisa Raspopovic
Peripheral neuropathy (PN) is the most common complication of diabetes. It is characterized by sensory loss which often causes major health consequences including foot ulceration, chronic pain, poor mobility and increased risk of falls. However, present treatments do not counteract the cause of the disease, namely lack of sensory feedback, but rather aim at partial and temporal symptoms relief (e.g. analgesics for pain or creams for ulcers healing). Electrical stimulation is a promising solution for sensory restoration, but it is yet unknown if it can elicit perceivable sensations in PN damaged nerves and whether it could lead to any health or functional benefits. To this aim, we designed a wearable sensory neuroprosthesis providing targeted neurostimulation at the ankle level (NeuroStep) restoring feet lost sensations. We tested it in 14 participants with PN, evaluating its effects on functional outcomes and pain, and the cortical activation related to the restored sensations. Our system was able to restore lost sensations in all participants. The nerves of PN participants resulted significantly less excitable and sensitive than healthy individuals (N=22). Thanks to the neurostimulation, participants improved cadence and functional gait, with even stronger improvements in individuals with higher risk of falls. A full day of NeuroStep use led to a clinically significant reduction of 30.4% ± 9.2% in neuropathic pain. Restored sensations activated cortical patterns, as measured via fMRI, similar to the naturally located foot sensations, thus not requiring training by the user. NeuroStep restores intuitive sensations in PN participants, improving mobility and decreasing pain, possibly replacing multiple inefficient treatments. It holds potential to drastically improve patients’ quality of life thanks to functional and health benefits, while paving the way to new effective neuromodulation treatments.
{"title":"Wearable neuroprosthesis improves mobility and reduces pain in neuropathic participants","authors":"Noemi Gozzi, Lauren Chee, Ingrid Odermatt, Sanne Kikkert, Greta Preatoni, Giacomo Valle, Nikolai Pfender, Felix Beuschlein, Nicole Wenderoth, Carl Zipser, Stanisa Raspopovic","doi":"10.1101/2024.05.08.24306164","DOIUrl":"https://doi.org/10.1101/2024.05.08.24306164","url":null,"abstract":"Peripheral neuropathy (PN) is the most common complication of diabetes. It is characterized by sensory loss which often causes major health consequences including foot ulceration, chronic pain, poor mobility and increased risk of falls. However, present treatments do not counteract the cause of the disease, namely lack of sensory feedback, but rather aim at partial and temporal symptoms relief (e.g. analgesics for pain or creams for ulcers healing). Electrical stimulation is a promising solution for sensory restoration, but it is yet unknown if it can elicit perceivable sensations in PN damaged nerves and whether it could lead to any health or functional benefits. To this aim, we designed a wearable sensory neuroprosthesis providing targeted neurostimulation at the ankle level (NeuroStep) restoring feet lost sensations. We tested it in 14 participants with PN, evaluating its effects on functional outcomes and pain, and the cortical activation related to the restored sensations. Our system was able to restore lost sensations in all participants. The nerves of PN participants resulted significantly less excitable and sensitive than healthy individuals (N=22). Thanks to the neurostimulation, participants improved cadence and functional gait, with even stronger improvements in individuals with higher risk of falls. A full day of NeuroStep use led to a clinically significant reduction of 30.4% ± 9.2% in neuropathic pain. Restored sensations activated cortical patterns, as measured via fMRI, similar to the naturally located foot sensations, thus not requiring training by the user. NeuroStep restores intuitive sensations in PN participants, improving mobility and decreasing pain, possibly replacing multiple inefficient treatments. It holds potential to drastically improve patients’ quality of life thanks to functional and health benefits, while paving the way to new effective neuromodulation treatments.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-07DOI: 10.1101/2024.05.06.24306931
HS Skarstad, KL Haganes, MAJ Sujan, TM Gellein, MK Johansen, KÅ Salvesen, JA Hawley, T. Moholdt
Time-restricted eating (TRE) is a nutritional intervention that confines the daily time-window for energy intake. TRE reduces fasting glucose concentrations in non-pregnant individuals, but whether this eating protocol is feasible and effective for glycemic control in pregnancy is unknown. The aim of this randomized controlled trial was to investigate the feasibility and effect of a 5-week TRE intervention among pregnant individuals at risk of gestational diabetes mellitus (GDM), compared with a usual-care control group. Participants underwent 2-h oral glucose tolerance tests and estimation of body composition, before and after the intervention. Interstitial glucose levels were continuously measured, and adherence rates and ratings of hunger were recorded daily. Thirty of 32 participants completed the trial. Participants allocated to TRE reduced their daily eating window from 12.3 (SD 1.3) to 9.9 (SD 1.0) h, but TRE did not affect glycemic measures, blood pressure, or body composition, compared with the control group. TRE increased hunger levels in the evening, but not in the morning, and induced only small changes in dietary intake. A 5-week TRE intervention was feasible for pregnant individuals with increased risk of GDM but had no effect on cardiometabolic outcomes.
限时进食（TRE）是一种限制每日能量摄入时间窗口的营养干预措施。限时进食可降低非孕妇的空腹血糖浓度，但这种进食方案对孕妇控制血糖是否可行和有效尚不清楚。这项随机对照试验的目的是研究在有妊娠糖尿病（GDM）风险的孕妇中开展为期 5 周的 TRE 干预的可行性和效果，并与常规护理对照组进行比较。参与者在干预前后接受了 2 小时口服葡萄糖耐量测试和身体成分评估。连续测量间质葡萄糖水平，每天记录坚持率和饥饿感评级。32 名参与者中有 30 人完成了试验。与对照组相比，接受 TRE 的参与者将每天的进食时间从 12.3 小时（标准差 1.3 小时）减少到 9.9 小时（标准差 1.0 小时），但 TRE 不会影响血糖测量、血压或身体成分。TRE会增加晚上的饥饿感，但不会增加早上的饥饿感，而且只会引起饮食摄入量的微小变化。为期 5 周的 TRE 干预对 GDM 风险增加的孕妇是可行的，但对心脏代谢结果没有影响。
{"title":"Feasibility of time-restricted eating during pregnancy and effect on glycemic control in people with increased risk of gestational diabetes – a randomized controlled trial","authors":"HS Skarstad, KL Haganes, MAJ Sujan, TM Gellein, MK Johansen, KÅ Salvesen, JA Hawley, T. Moholdt","doi":"10.1101/2024.05.06.24306931","DOIUrl":"https://doi.org/10.1101/2024.05.06.24306931","url":null,"abstract":"Time-restricted eating (TRE) is a nutritional intervention that confines the daily time-window for energy intake. TRE reduces fasting glucose concentrations in non-pregnant individuals, but whether this eating protocol is feasible and effective for glycemic control in pregnancy is unknown. The aim of this randomized controlled trial was to investigate the feasibility and effect of a 5-week TRE intervention among pregnant individuals at risk of gestational diabetes mellitus (GDM), compared with a usual-care control group. Participants underwent 2-h oral glucose tolerance tests and estimation of body composition, before and after the intervention. Interstitial glucose levels were continuously measured, and adherence rates and ratings of hunger were recorded daily. Thirty of 32 participants completed the trial. Participants allocated to TRE reduced their daily eating window from 12.3 (SD 1.3) to 9.9 (SD 1.0) h, but TRE did not affect glycemic measures, blood pressure, or body composition, compared with the control group. TRE increased hunger levels in the evening, but not in the morning, and induced only small changes in dietary intake. A 5-week TRE intervention was feasible for pregnant individuals with increased risk of GDM but had no effect on cardiometabolic outcomes.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"203 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-06DOI: 10.1101/2024.05.05.24306877
Mia D. Lee, Benjamin F. Voight
Background Susceptibility to type 2 diabetes mellitus (T2D) is driven by genetic and environmental risk factors. Dietary preferences are a modifiable and largely environmental risk factor for T2D. The role of diet in disease liability has been limited to observational and epidemiologic studies with mixed findings.
{"title":"Dietary preference and susceptibility to type 2 diabetes mellitus: a wide-angle Mendelian randomization study","authors":"Mia D. Lee, Benjamin F. Voight","doi":"10.1101/2024.05.05.24306877","DOIUrl":"https://doi.org/10.1101/2024.05.05.24306877","url":null,"abstract":"<strong>Background</strong> Susceptibility to type 2 diabetes mellitus (T2D) is driven by genetic and environmental risk factors. Dietary preferences are a modifiable and largely environmental risk factor for T2D. The role of diet in disease liability has been limited to observational and epidemiologic studies with mixed findings.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"218 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03DOI: 10.1101/2024.05.01.24306727
David P Kao, James Martin, Christina Aquilante, Elise L Shalowitz, Katarina Leyba, Elizabeth Kudron, Jane EB Reusch, Judith G. Regensteiner
Objective Determine whether statin-associated DM is reported more frequently in women than men in post-marketing adverse drug event (ADE) surveillance.
目的 在上市后药物不良事件 (ADE) 监测中，确定他汀类药物相关 DM 的报告女性是否多于男性。
{"title":"Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration","authors":"David P Kao, James Martin, Christina Aquilante, Elise L Shalowitz, Katarina Leyba, Elizabeth Kudron, Jane EB Reusch, Judith G. Regensteiner","doi":"10.1101/2024.05.01.24306727","DOIUrl":"https://doi.org/10.1101/2024.05.01.24306727","url":null,"abstract":"<strong>Objective</strong> Determine whether statin-associated DM is reported more frequently in women than men in post-marketing adverse drug event (ADE) surveillance.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-30DOI: 10.1101/2024.04.27.24306016
Sayali S. Deshpande-Joshi, Sonali S. Wagle, Madhura K. Deshmukh, Himangi Lubree, Hemant S. Damle, Suhas R. Otiv, Sanat B. Phatak, Rucha H. Wagh, K. Meenakumari, Smita N. Dhadge, Rajashree P. Kamat, Sayali G. Wadke, Deepa A. Raut, Dattatray S. Bhat, Souvik Bandyopadhyay, Chittaranjan S. Yajnik
Background Segregation of the effect of maternal size and glycemia on fetal growth is difficult to understand in overweight-obese women with diabetes.
背景 在患有糖尿病的超重-肥胖妇女中，很难理解母体体型和血糖对胎儿生长的影响。
{"title":"Neonatal Obesity-Adiposity is Largely Driven by Maternal Hyperglycemia in-utero: Analysis of Real-Life Data from a Diabetes Clinic in India","authors":"Sayali S. Deshpande-Joshi, Sonali S. Wagle, Madhura K. Deshmukh, Himangi Lubree, Hemant S. Damle, Suhas R. Otiv, Sanat B. Phatak, Rucha H. Wagh, K. Meenakumari, Smita N. Dhadge, Rajashree P. Kamat, Sayali G. Wadke, Deepa A. Raut, Dattatray S. Bhat, Souvik Bandyopadhyay, Chittaranjan S. Yajnik","doi":"10.1101/2024.04.27.24306016","DOIUrl":"https://doi.org/10.1101/2024.04.27.24306016","url":null,"abstract":"<strong>Background</strong> Segregation of the effect of maternal size and glycemia on fetal growth is difficult to understand in overweight-obese women with diabetes.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140829020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-27DOI: 10.1101/2024.04.25.24306391
Rebecca Schneider Aguirre, Tamara S Hannon, Robert V Considine, Yash Patel, M Sue Kirkman, Kieren J Mather
Background and Aims Identifying simple markers of risk for worsening glucose can allow care providers to target therapeutic interventions according to risk of worsening glycemic control. We aimed to determine which routine clinical measures herald near-term glycemic worsening in early type 2 diabetes(T2D).
{"title":"Predictors of glycemic worsening in the next year in adults with screen-detected type 2 diabetes","authors":"Rebecca Schneider Aguirre, Tamara S Hannon, Robert V Considine, Yash Patel, M Sue Kirkman, Kieren J Mather","doi":"10.1101/2024.04.25.24306391","DOIUrl":"https://doi.org/10.1101/2024.04.25.24306391","url":null,"abstract":"<strong>Background and Aims</strong> Identifying simple markers of risk for worsening glucose can allow care providers to target therapeutic interventions according to risk of worsening glycemic control. We aimed to determine which routine clinical measures herald near-term glycemic worsening in early type 2 diabetes(T2D).","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140829242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.1101/2024.04.15.24305840
Carlos A. Fermín-Martínez, Omar Yaxmehen Bello-Chavolla, César Daniel Paz-Cabrera, Daniel Ramírez-García, Jerónimo Perezalonso-Espinosa, Luisa Fernández-Chirino, Arsenio Vargas-Vázquez, Juan Pablo Díaz-Sánchez, Padme Nailea Méndez-Labra, Alejandra Núñez-Luna, Martín Roberto Basile-Alvarez, Paulina Sánchez-Castro, Fiona Bragg, Louisa Gnatiuc Friedrichs, Diego Aguilar-Ramírez, Jonathan R. Emberson, Jaime Berumen-Campos, Pablo Kuri-Morales, Roberto Tapia-Conyer, Jesus Alegre-Díaz, Jacqueline A. Seiglie, Neftali Eduardo Antonio-Villa
BACKGROUND Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations.
{"title":"Prediabetes as a risk factor for all-cause and cause-specific mortality: a prospective analysis of 115,919 adults without diabetes in Mexico City","authors":"Carlos A. Fermín-Martínez, Omar Yaxmehen Bello-Chavolla, César Daniel Paz-Cabrera, Daniel Ramírez-García, Jerónimo Perezalonso-Espinosa, Luisa Fernández-Chirino, Arsenio Vargas-Vázquez, Juan Pablo Díaz-Sánchez, Padme Nailea Méndez-Labra, Alejandra Núñez-Luna, Martín Roberto Basile-Alvarez, Paulina Sánchez-Castro, Fiona Bragg, Louisa Gnatiuc Friedrichs, Diego Aguilar-Ramírez, Jonathan R. Emberson, Jaime Berumen-Campos, Pablo Kuri-Morales, Roberto Tapia-Conyer, Jesus Alegre-Díaz, Jacqueline A. Seiglie, Neftali Eduardo Antonio-Villa","doi":"10.1101/2024.04.15.24305840","DOIUrl":"https://doi.org/10.1101/2024.04.15.24305840","url":null,"abstract":"<strong>BACKGROUND</strong> Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"108 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140612607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：